ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by AlphaQuest LLC

AlphaQuest LLC decreased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 94.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 516 shares of the specialty pharmaceutical company’s stock after selling 9,377 shares during the quarter. AlphaQuest LLC’s holdings in ANI Pharmaceuticals were worth $29,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Pacer Advisors Inc. boosted its stake in ANI Pharmaceuticals by 23,259.8% in the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock worth $33,907,000 after purchasing an additional 565,910 shares during the period. JPMorgan Chase & Co. boosted its stake in ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after purchasing an additional 340,854 shares during the period. abrdn plc acquired a new position in ANI Pharmaceuticals in the 4th quarter worth approximately $13,155,000. Bank of Montreal Can acquired a new position in ANI Pharmaceuticals in the 3rd quarter worth approximately $13,043,000. Finally, Barclays PLC boosted its stake in ANI Pharmaceuticals by 1,681.2% in the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock worth $8,534,000 after purchasing an additional 135,003 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on ANIP. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 14th. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They set a “buy” rating and a $80.00 target price for the company. Finally, Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.75.

Insider Activity at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the completion of the sale, the senior vice president now owns 66,525 shares of the company’s stock, valued at approximately $4,048,711.50. The trade was a 1.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. The trade was a 0.49 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,200 shares of company stock valued at $191,776. Insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Stock Down 0.1 %

ANIP stock opened at $64.26 on Friday. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.81. The company has a fifty day simple moving average of $59.39 and a 200 day simple moving average of $58.17. The firm has a market cap of $1.40 billion, a PE ratio of -116.84 and a beta of 0.63.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.